The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to an agency press release.Atacicept-vymj (Trutakna, Vera Therapeutics) is the first approved medication to target both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in immunoglobulin A (IgA) nephropathy.Approval was based on a prespecified interim analysis…
Source: Healio News
